Although these studies seem to suggest that the compete elimination of IL-17A favor the migration of CD8+ T cells to tumor sites leading to augmentation of antitumor immunity, the cytotoxic activity of TILs is not fully understood. The gene discussed is CD8A; the disease is neoplasm.